Kaisa Health Group Holdings Limited (0876) AI Stock Analysis

• Market Cap: €332.78M
• Dividend Yield: N/A
• Average Volume (3M): 76.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: -8.46%
• EPS Growth: 45.13%
• Country: HK
• Employees: 861
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 5,042,139,000
• 10 Day Avg. Volume: 53,429,215
• 30 Day Avg. Volume: 76,644,739
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.65
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's financial challenges, including persistent net losses and negative cash flows. Despite strong technical indicators suggesting bullish momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation. The absence of earnings call data and corporate events means these factors do not influence the score.

Kaisa Health Group Holdings Limited Business Overview & Revenue Model

Company Description

Kaisa Health Group Holdings Limited (0876) is a diversified health and wellness company based in Hong Kong. The company operates primarily in the healthcare and wellness sectors, focusing on providing innovative health solutions, medical services, and wellness products. It aims to enhance the quality of life through a range of offerings, including health supplements, medical equipment, and health management services.

How the Company Makes Money

Kaisa Health Group Holdings Limited generates revenue through several key streams. Primarily, the company earns income from the sale of health supplements and wellness products, which are marketed through various retail and online channels. Additionally, Kaisa Health provides medical services, including consultations and health management programs, which contribute to its revenue. The company may also engage in partnerships with healthcare providers and distributors, enhancing its market reach and operational efficiency. Significant collaborations with hospitals or health institutions could further bolster revenue, while the growing demand for health and wellness solutions in Asia presents opportunities for expansion and increased profitability.

Kaisa Health Group Holdings Limited Financial Statement Overview

Summary

Kaisa Health Group Holdings Limited faces significant financial challenges, including persistent net losses and negative operating cash flows. While the balance sheet reflects a strong cash position and low leverage, declining equity and asset values are concerning. The company needs to improve profitability and cash flow generation to enhance its financial health and sustain long-term operations.

Income Statement

The company has struggled with profitability, showing consistent net losses in recent years, including a significant net loss of $46.36 million in 2024. Revenue growth is stagnant, with a slight decline from 2023 to 2024. Gross profit margins are relatively stable but have not translated into operating profits, as evidenced by negative EBIT and EBITDA margins in 2024. Overall, the income statement reflects challenges in revenue growth and profitability.

Balance Sheet

The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.02 in 2024. Stockholders' equity has decreased over the years, impacting the equity ratio, which remains decent at 83.31% in 2024. The company maintains a strong cash position, with cash and short-term investments exceeding total debt. However, the decline in total assets and stockholders' equity over recent years raises concerns about long-term financial stability.

Cash Flow

The cash flow statement indicates challenges in generating positive cash flows. Operating cash flow was zero in 2024, and the company has recorded negative free cash flow in prior years. The inability to generate positive cash flow from operations is a critical weakness. The lack of capital expenditures in the latest year suggests potential underinvestment in growth opportunities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	166.42M	185.36M	185.88M	191.50M	209.63M	183.81M
Gross Profit	69.20M	81.86M	81.07M	82.56M	97.42M	89.96M
EBITDA	-18.85M	-12.70M	27.56M	-132.02M	45.58M	-20.71M
Net Income	-31.22M	-46.35M	7.47M	-123.32M	2.36M	-39.69M
Balance Sheet
Total Assets	513.07M	517.59M	605.07M	767.60M	971.33M	757.54M
Cash, Cash Equivalents and Short-Term Investments	146.95M	149.61M	174.08M	173.45M	259.26M	176.60M
Total Debt	11.37M	10.65M	18.00M	31.87M	32.28M	23.24M
Total Liabilities	82.16M	91.10M	113.30M	296.69M	288.49M	110.04M
Stockholders Equity	435.90M	431.15M	492.01M	485.33M	651.12M	636.52M
Cash Flow
Free Cash Flow	-10.46M	-37.31M	-45.51M	-81.53M	-137.09M	-59.42M
Operating Cash Flow	-7.59M	-32.32M	-34.64M	-67.53M	-122.00M	-29.18M
Investing Cash Flow	15.64M	23.42M	44.50M	2.02M	141.67M	-21.66M
Financing Cash Flow	-3.14M	-7.82M	-7.34M	-7.08M	70.09M	-6.59M

Kaisa Health Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0876, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.98 is Neutral, neither overbought nor oversold. The STOCH value of 48.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0876.

Kaisa Health Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	83 Outperform	€10.68B	17.58	23.40%	2.85%	6.51%	4.85%
1358	74 Outperform	€2.12B	13.75	3.76%	6.98%	21.39%	-0.57%
2276	74 Outperform	HK$22.89B	39.61	24.57%	0.70%	13.58%	24.59%
1501	70 Neutral	HK$5.37B	25.94	10.31%	0.98%	14.06%	3.02%
1066	68 Neutral	HK$24.42B	11.59	8.34%	4.48%	0.74%	2.13%
0876	54 Neutral	€332.78M	-12.42	―	―	-8.46%	45.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kaisa Health Group Holdings Limited Corporate Events

Kaisa Health Group Appoints New Vice Chairperson

Kaisa Health Group Holdings Limited has announced the appointment of Ms. Luo Tingting as the Vice Chairperson of its Board, effective from September 23, 2025. Ms. Luo, who has been with Kaisa Group since 2011, brings extensive experience in financial management, having served in various leadership roles within the company. This appointment is expected to strengthen the company’s leadership team and potentially enhance its strategic direction in the health industry.

Kaisa Health Group Updates Board of Directors

Kaisa Health Group Holdings Limited has announced an updated list of its board of directors, effective from 23 September 2025. The announcement outlines the roles and functions of both executive and independent non-executive directors, as well as the composition of the audit, remuneration, and nomination committees. This restructuring may impact the company’s strategic direction and governance, potentially influencing its market position and stakeholder relations.

Kaisa Health Reports Reduced Losses and Positive Comprehensive Income for H1 2025

Kaisa Health Group Holdings Limited reported its interim results for the six months ended June 30, 2025, showing a decrease in revenue to HK$69.6 million from HK$88.5 million in the same period of 2024. Despite a reduction in losses compared to the previous year, the company still recorded a loss of HK$9.3 million. The announcement highlights a positive shift in total comprehensive income due to favorable exchange differences, suggesting potential improvements in the company’s financial health and market positioning.

Kaisa Health Group Reports Reduced Losses for H1 2025

Kaisa Health Group Holdings Limited has announced a significant reduction in its financial losses for the first half of 2025. The company expects its losses to decrease to between HK$9 million and HK$10 million, compared to a loss of approximately HK$24 million in the same period of 2024. This improvement is primarily attributed to a gain from changes in financial assets valued at fair value through profit or loss, amounting to approximately HK$9 million. The interim results are still being finalized and have not been audited, with further details to be disclosed in due course.

Kaisa Health Group Schedules Board Meeting to Review Interim Results

Kaisa Health Group Holdings Limited announced that its board of directors will meet on August 27, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, which could impact shareholder returns and market perception.